GLP-1 receptor agonists like semaglutide and tirzepatide reduce appetite centrally while improving insulin sensitivity
Special considerations for different GLP-1 delivery methods Not all GLP-1 medications come as traditional injections, and the delivery method affects site selection considerations
Important Note: Seek urgent medical care for trouble breathing, swelling of the face or throat, widespread hives, dizziness, or symptoms that suggest a serious allergic reaction
The "SAVE $60" label on the 6-package option references a comparison price that isn't explicitly stated on the main page
Quick Answer: Tirzepatide may cause or worsen GERD in some patients, though the relationship is not fully established and GERD is not prominently featured in FDA labeling
This is a phase 3, multicenter, randomized, placebo-controlled, double- blinded clinical trial investigating the efficacy and safety of maximum tolerated dose (MTD) of tirzepatide (10 mg or 15 mg) administered once weekly (QW) subcutaneously compared with placebo for body weight management, in participants who have obesity, or overweight with at least 1 obesity-related complication (excluding type 2 diabetes), and with at least 5% weight reduction following a 12-week intensive lifestyle intervention lead-in